Accelerating AI-driven breast cancer screening with globally diverse, pathology-confirmed mammography datasets

Background

Breast cancer remains one of the most common malignancies worldwide, and screening programs play a central role in detecting disease at earlier, more treatable stages¹.

AI is increasingly used to support radiologists by highlighting subtle findings, reducing false negatives, and improving reading efficiency in screening workflows².

Newer AI approaches in this field often integrate multimodal data to deliver more precise, context-aware risk and diagnostic assessments³.

Objective

A U.S.-based medical technology company partnered with Aigora to obtain geographically diverse, pathology-confirmed imaging datasets to support the development, validation, and FDA clearance of multiple AI-enabled breast cancer screening algorithms.

Delivery

Aigora curated and delivered globally sourced, regulatory-grade mammography datasets with diagnoses confirmed through pathology or long-term imaging follow-up.